June 12, 2007 - Ablation Frontiers, Inc., developer and manufacturer of three-dimensional catheters for the treatment of atrial fibrillation (AF), announced that it received the CE Mark for its Cardiac Ablation System consisting of a portfolio of anatomical based catheters and a uniquely designed radiofrequency (RF) energy delivery system, for which the company initiated the first commercial use of its Ablation System this year at key international cardiac centers throughout the European Union and other International markets that recognize the CE Mark.
Ablation Frontiers proprietary products are designed to treat all types of atrial fibrillation, including patients with paroxysmal, persistent and the more difficult to treat, permanent AF. The novel catheters effectively treat tissue in the right and/or left atrium through percutaneous access to the heart. Ablation Frontiers, Inc. has developed a toolkit of catheters specifically designed for the atrial anatomy and AF ablation. The catheters are powered by a RF energy source that allows a physician to precisely control the energy and tailor treatment for the individual needs of the patient. Design goals centered on the need to develop a very simple but elegant therapy solution that could greatly reduce procedure times, improve safety and be easily learned by most electrophysiologists. Unlike all other treatment approaches, this technology does not rely on three-dimensional mapping or catheter steering robotics, but the percutaneous cardiac catheters are inserted through a patient’s leg vein and advanced into the right and/or left atrium. Each catheter is designed to map, and using radiofrequency energy, ablate specific target sites through simultaneous selective combinations of multiple electrode channels.
For more information: www.ablationfrontiers.com
April 29, 2026 
